title: Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
abstract: Human epidermal growth factor receptor-2 (HER-2) overexpression in breast cancer occurs in 20% to 30% of patients with breast cancer. Trastuzumab (Herceptin) targets HER-2 tyrosine kinase receptors expressed on tumor cells and mediates anti-proliferative effects against HER-2-positive tumor cells. Adjuvant chemotherapy with trastuzumab has improved the prognosis of patients with HER-2 positive high-grade breast cancer. However, patients often experience appearance and proliferation of recurrent tumor cells after trastuzumab treatment. In this study, we report the successful establishment and characterization of a cell line (BTIC) derived from a patient with recurrent breast cancer after adjuvant chemotherapy with trastuzumab. Characteristics of the BTIC cell line were investigated by phase contrast or electron microscopic observations, chromosome analysis, xenotransplantation, immunohistochemistry and radioimmunoassay for tumor markers. We confirmed that the BTIC cell line grown as multilayered culture in culture dishes, has a poorly developed endoplasmic reticulum in the cytoplasm and some desmosomes. The population doubling time was approximately 44 hr. A graft in nude mouse after xenotransplantation was diagnosed as scirrhous carcinoma. Immunohistochemistry on cultured BTIC cells revealed that the BTIC cells were negative for estrogen receptor and progesterone receptor, and 30% positive for HER-2. Radioimmunoassay indicated secretion of HER-2 protein, NCC-ST-439 and CA15-3.
authors.affiliation: Department of Anatomy II, Jikei University School of Medicine, Tokyo, Japan. ninomiya@33club.co.jp
authors.forename: Kouzou
authors.initials: K
authors.lastname: Ninomiya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohi
authors.forename: Isao
authors.initials: I
authors.lastname: Tabei
authors.forename: Song
authors.initials: S
authors.lastname: Jin
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tachibana
authors.forename: Shigeo
authors.initials: S
authors.lastname: Yamashita
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
authors.forename: Hisashi
authors.initials: H
authors.lastname: Hashimoto
mesh_terms: D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000473:pathology*; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D008854:Microscopy, Electron; D009364:Neoplasm Recurrence, Local; D009368:Neoplasm Transplantation; D010996:Pleural Effusion / Q000473:pathology*; D014183:Transplantation, Heterologous; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000068878:Trastuzumab